This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uy, H. L. Articles by Guise, T. A. Search for Related Content PubMed PubMed Citation Articles by Uy, H. L. Articles by Guise, T. A.

Tumor Necrosis Factor Enhances Parathyroid Hormone-related Protein-induced Hypercalcemia and Bone Resorption without Inhibiting Bone Formation in Vivo¹

Departments of Medicine [H. L. U., J. J. Y., G. D. R., T. A. G.] and Pathology [B. F. B., B. M. S.], University of Texas Health Sciences Center, San Antonio, Texas 78284-7877; Audie Murphy Veterans Affairs Medical Center, San Antonio, Texas 78284 [H. L. U., G. R. M., G. D. R.]; and Amgen, Inc., Thousand Oaks, California 91320 [C. R. D.]

Humoral hypercalcemia of malignancy results from the effects of tumor-produced factors on bone, kidney, and intestine that disrupt normal calcium homeostasis. Although parathyroid hormone-related protein (PTHrP) is a major mediator of the syndrome, tumors also produce other hypercalcemic factors, such as tumor necrosis factor (TNF), which may modulate the effects of PTHrP. It has been postulated that TNF may counteract the stimulatory effects of PTHrP on bone formation. To examine the effects of TNF on PTHrP-induced changes in calcium and bone metabolism, a murine tumor model of hypercalcemia was used. Nude mice were inoculated with Chinese hamster ovarian (CHO) cells expressing human TNF (CHO/TNF) or nontransfected CHO cells (CHO/-) and further treated with injections of human PTHrP(1–34) or vehicle. The effects of TNF, PTHrP, and the combination of the two factors on blood ionized calcium, osteoclast recruitment, and bone histomorphometry were evaluated. Mice bearing CHO/TNF tumors that were injected with PTHrP had significantly higher calcium concentrations, increased committed osteoclast progenitors, and mature osteoclasts as well as enhanced bone resorption compared with mice bearing CHO/TNF tumors injected with vehicle or those bearing CHO/- tumors injected with PTHrP or vehicle. A 2-fold increase in new woven bone formed in the calvaria at sites of previous bone resorption was observed in CHO/TNF mice treated with PTHrP. Bone formation rates in the vertebrae were similar in both CHO/- and CHO/TNF mice treated with PTHrP. These data demonstrate that the hypercalcemic effects of PTHrP are enhanced by TNF and that this effect is due to the increased production of committed osteoclast precursors with a subsequent increase in osteoclastic bone resorption. Furthermore, PTHrP caused a coupled increase in osteoclastic bone resorption and new bone formation that was not inhibited by TNF. These findings highlight the complex interactions that may occur between tumor-produced factors on bone that result in malignancy-associated hypercalcemia and suggest that TNF may not be responsible for the decreased bone formation seen in some patients with this condition.

¹ This work was supported by Grants AR 01899 and CA 40035 from the NIH.

² To whom requests for reprints should be addressed, at Division of Endocrinology, Department of Medicine, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7877.

Received 12/ 6/96. Accepted 5/27/97.

This article has been cited by other articles:

				H. A. Al-Mashat, S. Kandru, R. Liu, Y. Behl, T. Desta, and D. T. Graves Diabetes Enhances mRNA Levels of Proapoptotic Genes and Caspase Activity, Which Contribute to Impaired Healing Diabetes, February 1, 2006; 55(2): 487 - 495. [Abstract] [Full Text] [PDF]

				J.-h. Wang, M. Pazianas, W. D. Fraser, F. Harris, and J. B. Eastwood Acute renal failure and hypercalcaemia in a man from Guyana: what is the link? Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1505 - 1508. [Full Text] [PDF]

				B. O. Oyajobi, G. Franchin, P. J. Williams, D. Pulkrabek, A. Gupta, S. Munoz, B. Grubbs, M. Zhao, D. Chen, B. Sherry, et al. Dual effects of macrophage inflammatory protein-1{alpha} on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood, July 1, 2003; 102(1): 311 - 319. [Abstract] [Full Text] [PDF]

				M. Zhao, S. E. Harris, D. Horn, Z. Geng, R. Nishimura, G. R. Mundy, and Di Chen Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation J. Cell Biol., June 10, 2002; 157(6): 1049 - 1060. [Abstract] [Full Text] [PDF]

				K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text]

				G. D. Roodman Biology of Osteoclast Activation in Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3562 - 3571. [Abstract] [Full Text] [PDF]

				A. Daroszewska, R. C Bucknall, P. Chu, and W. D Fraser Severe hypercalcaemia in B-cell lymphoma: combined effects of PTH-rP, IL-6 and TNF Postgrad. Med. J., November 1, 1999; 75(889): 672 - 674. [Abstract] [Full Text]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]